Refine by
Preclinical Animal Models Equipment & Supplies
133 equipment items found
Manufactured by:GENFIT based inLoos, FRANCE
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models. NTZ is currently being evaluated in an investigator-initiated proof-of-concept clinical trial for the potential ...
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS00X has demonstrated pre-clinical efficacy in 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis. ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
In vivo application of ENKASTIM-iv, an Hsp70-based GMP-grade synthetic peptide comprising 14 amino acids (14mer), results in a specific activation of NK cells which acquire the capacity to recognise and kill membrane Hsp70-positive tumors and ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Schizophrenia is a chronic disease that manifests through disturbances of perception, thought, cognition, emotion, motivation and motor activity. Over a lifetime, about 1% of the population will develop ...
by:Healx Ltd. based inCambridge, UNITED KINGDOM
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to patients ...
Manufactured by:Elpiscience based inShanghai, CHINA
OX40, also known as CD134, is a member of the tumor necrosis factor (TNF) receptor family and is an important co-stimulator of T cell responses. Typically for TNF receptor family members, 3 molecules of OX40 bind to the trimeric OX40 ligand-protein, activating downstream NF-κB, PI3K, and AKT pathways, which lead to increased cytokine production. Activation of OX40 enhances T-cell expansion, ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-0184 is an investigational inhibitor of activin receptor-like kinase 2 (ALK2) and ALK5 (also known as TGFβR1). This bimodal inhibitor is believed to downregulate multiple TGF-β superfamily signaling pathways and has shown antitumor activity in several ...
by:Genmab A/S based inCopenhagen V, DENMARK
GEN3014 (HexaBody®-CD38) is a novel human CD38 monoclonal antibody incorporating Genmab’s HexaBody® technology. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody®-CD38. In preclinical models of hematological malignancies, HexaBody®-CD38 demonstrated enhanced ...
Manufactured by:Suono Bio based inFoxborough, MASSACHUSETTS (USA)
We have reimagined ultrasound as a simple and effective delivery platform, which acts on the therapeutic molecules themselves, achieving ultra-rapid, formulation-independent drug delivery. This enables us to “push” virtually any therapeutic class, including temperamental molecules, like nucleic acids, directly into cells with astounding efficacy and accuracy, affecting historically ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Many of the childhood-onset intractable epilepsy conditions within the expanded access program share considerable overlap with ASD and these conditions often fall within the orphan disease space. Initial clinical observations from treating physicians suggest a potential role for cannabinoids in addressing problems associated with ASD such as deficits in cognition, behavior, and ...
Manufactured by:EPED Inc. based inKaohsiung City, TAIWAN
The Most Flexible Augmented-Reality Simulator in Dental Clinical Training Education. SimEx is the most adaptive Augmented-Reality Simulator currently in today’s marketplace, enabling any dental school to select what typodont to use,and to customize the technology to their school’s speciï¬c ...
Manufactured by:Altimmune Inc. based inGaithersburg, MARYLAND (USA)
A peptide-based dual GLP-1/glucagon receptor agonist designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis (NASH). NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD), involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, leading to fibrosis or eventually ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of cancer death. The clinical candidate is a first-in-class, GPC3-FcA-LNP, with a strong preclinical profile supporting its advance into this ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
Destiny Pharma is working in collaboration with SporeGen Limited, a UK biotechnology company working exclusively on Bacillus and its applications, to co-develop SporeGen’s SPOR-COV™ product as a novel, preventive treatment for COVID-19. SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment. ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, which is advantageous when bystander cells are cancerous but toxic if the cytotoxic drug is able to enter adjacent healthy cells. The DolaLock payload ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung ...
Manufactured by:TargetMol Chemicals Inc. based inWellesley Hills, MASSACHUSETTS (USA)
RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor ...